Emerging Hypervirulent Marek's Disease Virus Variants Significantly Overcome Protection Conferred by Commercial Vaccines (2023)
Attributed to:
Dissecting the molecular pathways of MDV oncoprotein Meq for understanding pathogenesis and aid vaccine development
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3390/v15071434
PubMed Identifier: 37515122
Publication URI: http://europepmc.org/abstract/MED/37515122
Type: Journal Article/Review
Parent Publication: Viruses
Issue: 7
ISSN: 1999-4915